Press Releases
If you want to subscribe to our press releases please go to the Cision site where it is possible to subscribe.
Note: After January 21, 2020, all press releases are published in English as original language.
Older news
ExpreS2ion signs commercial license agreement with ABIVAX for using the ExpreS2 platform in their Ebola program
Horsholm, Denmark, April 20, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]
ExpreS2ion files joint-patent on the production of an improved malaria vaccine with the Walter and Eliza Hall Institute of Medical Research
Horsholm, Denmark, April 6, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]
ExpreS2ion Biotech Holding AB announces that the OptiFemVac Consortium has received final Eurostars approval of its grant application for development of a novel Zika vaccine
Hørsholm, Denmark, March 30, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS […]
ExpreS2ion’s Licensee, VaxInnate, is Winding Down Operations
Horsholm, Denmark, February 9, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
ExpreS2ion announces the initial approval of a Eurostars grant application, OptiFemVac, with main focus on the development of a Zika vaccine
Horsholm, Denmark, January 23, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
ExpreS2ion and ABIVAX announce development collaboration on the Ebola prophylaxis and treatment program, ABX544
Horsholm, Denmark and Paris, France, December 12, 2016 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion […]
ExpreS2ion announces the initiation of a Phase I/IIa clinical trial for a new blood-stage malaria vaccine
Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, the Jenner Institute […]
ExpreS2ion and VaxInnate Sign Research License Agreement
Horsholm, Denmark, September 20, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), and VaxInnate Corporation (“VaxInnate”) announce that they have […]
ExpreS2ion Biotech Holding AB: Första dag för handel på Nasdaq Stockholm First North
Idag, den 29 juli 2016, inleds handeln i ExpreS2ion Biotech Holding AB:s (”ExpreS2ion”) aktier på Nasdaq Stockholm First North. Handel […]
ExpreS2ion Biotech announces clinical trial update for the PamVac (Placental Malaria Vaccine) phase I study
ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical […]
ExpreS2ion Biotech Holding AB approved for listing on Nasdaq Stockholm First North
ExpreS2ion Biotech Holding AB (“ExpreS2ion “) announces that the Company has met the requirements for listing on Nasdaq Stockholm First […]
ExpreS2ion Biotech Holding AB: Listing process delayed
ExpreS2ion Biotech Holding AB herby announces that the listing process at Nasdaq Stockholm First North has been delayed. The company […]
ExpreS2ion Biotech Holding AB’s initial public offering oversubscribed
The 22 June 2016 the subscription period in ExpreS2ion Biotech Holding AB’s (”ExpreS2ion”) initial public offering (”IPO”) of shares at […]
ExpreS2ion Biotech Announces Grant of US Patent
Today, June 21, 2016, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion Biotech”) announce that its fundamental […]
Today the subscription period of ExpreS2ion Biotech Holding AB’s Initial Public Offering begins
Today, June 8, 2016, the subscription period commences regarding ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) initial public offering before the planned […]
ExpreS2ion Biotech Holding AB publishes memorandum in advance of the Initial Public Offering
ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes the memorandum for the Initial Public Offering which the company plans to commence […]
ExpreS2ion Biotech Holding AB is planning an Initial Public Offering and listing on Nasdaq Stockholm First North
ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby announces on May 26th 2016 that the company is planning an Initial Public Offering […]